<DOC>
	<DOC>NCT01662531</DOC>
	<brief_summary>This study will examine the pharmacokinetics, safety and efficacy of rIX-FP for the control and prevention of bleeding episodes in children who have previously received factor replacement therapy for hemophilia B.</brief_summary>
	<brief_title>A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Male subjects, younger than 12 years old. Severe hemophilia B (Factor IX [FIX] activity of ≤ 2%). Body weight ≥ 10 kg. Subjects who have received FIX products (plasmaderived and/or recombinant FIX) for &gt; 150 exposure days (EDs) (6 to &lt; 12 years), and &gt; 50 EDs (&lt; 6 years). No history of FIX inhibitor formation, no detectable inhibitors at Screening and no family history of inhibitors against FIX. Written informed consent for study participation. Known hypersensitivity to any FIX product or hamster protein. Known congenital or acquired coagulation disorder other than congenital FIX deficiency. Kidney or liver disease. Recent lifethreatening bleeding episode.</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>